Anna Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anna Lee has a total of 473 co-authors. Here are the top co-authors by number of shared publications:
David Schreiber
Department of Radiation Oncology, SUNY Downstate Medical Center, Brooklyn, New York
28 shared publications- Virginia Wedell Osborn
Radiation Oncology, SUNY Downstate Medical Center & Veterans Affairs, New York Harbor Healthcare System
16 shared publications David Schwartz
11 shared publicationsJoseph Safdieh
Kings County Hospital Center, Brooklyn, NY, USA
10 shared publications- Ashley Albert
Radiation Oncology, University of Mississippi Medical Center, Jackson, USA
8 shared publications - Babak Givi
Department of Otolaryngology—Head and Neck Surgery NYU Langone Health New York New York USA
7 shared publications
Latest Publications
- Open Access
Magnetic Resonance Imaging Simulation of the Skull Base, Oral Cavity, Pharynx, and Larynx: Advanced Imaging Protocol for a Radiation Oncology Center
Head and neck radiation oncology, with its complex locality and epidemiology, requires various imaging techniques to achieve sufficient visualization. Through collaboration with medical physicists, radiation therapists, radiation oncologists, and neuroradiologists, our group clinically implemented a standard set of magnetic resonance imaging (MRI) sequences on an MR-simulation scanner for three anatomical regions: skull base, oral cavity, and larynx/pharynx. A total of 41 patients with head and neck cancer and 3 volunteers were scanned on either a 1.5T or 3T MR-simulation scanner. Sequences described include Dixon-based approaches, SPAIR-based approaches, short T2-based approaches, and quantitative imaging methods. We describe and outline the steps to optimize these notable MRI sequences to aid in successful implementation in a radiation oncology clinic.
Open AccessMagnetic Resonance Imaging Simulation of the Skull Base, Oral Cavity, Pharynx, and Larynx: Advanced Imaging Protocol for a Radiation Oncology Center
Head and neck radiation oncology, with its complex locality and epidemiology, requires various imaging techniques to achieve sufficient visualization. Through collaboration with medical physicists, radiation therapists, radiation oncologists, and neuroradiologists, our group clinically implemented a standard set of magnetic resonance imaging (MRI) sequences on an MR-simulation scanner for three anatomical regions: skull base, oral cavity, and larynx/pharynx. A total of 41 patients with head and neck cancer and 3 volunteers were scanned on either a 1.5T or 3T MR-simulation scanner. Sequences described include Dixon-based approaches, SPAIR-based approaches, short T2-based approaches, and quantitative imaging methods. We describe and outline the steps to optimize these notable MRI sequences to aid in successful implementation in a radiation oncology clinic.
- 8 June 2026
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 125 (3) , 684-685
The Quiet Neck in Esthesioneuroblastoma
- 8 June 2026
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 125 (3) , 684-685
The Quiet Neck in Esthesioneuroblastoma
- Open Access
- 1 October 2025
- Published by UT MD Anderson Cancer Center Research Medical Library in Advances in Cancer Education and Quality Improvement
- Vol. 1 (2) , 6
Designing an Electronic Patient-Reported Outcomes Information Infrastructure Supported by the RE-AIM Implementation Framework
Objective: Patient-reported outcomes (PROs) contain valuable information that can be leveraged by providers to perform timely interventions and improve quality of life and survival. However, the implementation of electronic PROs (ePROs) remains a challenge from technical and evaluation perspectives. Our objective was to construct a robust electronic health record (EHR)-integrated ePRO information infrastructure founded on RE-AIM (reach-effectiveness-adoption-implementation-maintenance) principles. Materials and Methods: We used Epic Systems as our EHR platform to build the MD Anderson Symptom Index Head and Neck Module (MDASI-HN) for release to all patients undergoing evaluation and/or treatment in our HN Radiation Oncology clinics. RE-AIM metrics were established and used to design patient, provider, and implementing facilitator information tools. Results: From January 2021 to July 2024, our ePRO program has collected 13,156 patient-submitted ePROs on 3,497 unique HN patients, with a 12-month sustained ePRO compliance rate of 82%. We also propose a dynamic 2-cycle implementation model. This model can be used to continuously (re)define, build, and adapt ePRO information tools for patients, providers, and program facilitators. Discussion: Our ePRO framework has several benefits, including integrated clinical data for enhanced decision-making, potential scalability, and use of a common EHR system. Formative (ie, mid-phase) evaluations were essential to our program, allowing for timely optimization of ePRO compliance, ePRO usage by clinical staff, and secondary use of high-quality ePRO data. Conclusion: In this article, we provide a valuable roadmap toward developing a comprehensive, EHR-based ePRO information infrastructure simultaneously optimized for clinical utility, informatics operations, and implementation evaluation founded on RE-AIM principles.
- 1 October 2025
- Published by UT MD Anderson Cancer Center Research Medical Library in Advances in Cancer Education and Quality Improvement
- Vol. 1 (2) , 6
Open AccessDesigning an Electronic Patient-Reported Outcomes Information Infrastructure Supported by the RE-AIM Implementation Framework
Objective: Patient-reported outcomes (PROs) contain valuable information that can be leveraged by providers to perform timely interventions and improve quality of life and survival. However, the implementation of electronic PROs (ePROs) remains a challenge from technical and evaluation perspectives. Our objective was to construct a robust electronic health record (EHR)-integrated ePRO information infrastructure founded on RE-AIM (reach-effectiveness-adoption-implementation-maintenance) principles. Materials and Methods: We used Epic Systems as our EHR platform to build the MD Anderson Symptom Index Head and Neck Module (MDASI-HN) for release to all patients undergoing evaluation and/or treatment in our HN Radiation Oncology clinics. RE-AIM metrics were established and used to design patient, provider, and implementing facilitator information tools. Results: From January 2021 to July 2024, our ePRO program has collected 13,156 patient-submitted ePROs on 3,497 unique HN patients, with a 12-month sustained ePRO compliance rate of 82%. We also propose a dynamic 2-cycle implementation model. This model can be used to continuously (re)define, build, and adapt ePRO information tools for patients, providers, and program facilitators. Discussion: Our ePRO framework has several benefits, including integrated clinical data for enhanced decision-making, potential scalability, and use of a common EHR system. Formative (ie, mid-phase) evaluations were essential to our program, allowing for timely optimization of ePRO compliance, ePRO usage by clinical staff, and secondary use of high-quality ePRO data. Conclusion: In this article, we provide a valuable roadmap toward developing a comprehensive, EHR-based ePRO information infrastructure simultaneously optimized for clinical utility, informatics operations, and implementation evaluation founded on RE-AIM principles.
- Open Access
Sleep-related symptoms are associated with survival in oropharyngeal cancer radiotherapy survivors: Temporal characterization of patient-reported outcomes in a large-scale prospective longitudinal cohort
Purpose: Sleep-related symptom prevalence is not well-characterized and likely under-recognized in head and neck cancer. We investigated longitudinal symptom severity trajectory, prevalence of moderate/severe symptoms, and association between severe sleep-related patient-reported symptoms and oncologic endpoints in oropharyngeal cancer (OPC) patients receiving radiotherapy (RT). Methods: A longitudinal cohort of 372 patients with OPC treated with curative-intent RT with/without chemotherapy at a single-site tertiary center was queried at RT start, end of RT, and six months post-RT. All completed baseline MD Anderson Symptom Inventory-Head and Neck (MDASI-HN) at start of RT. Sleep-related symptom items included “fatigue”, “disturbed sleep”, and “drowsiness” (mild, moderate, severe). Clinical data were collected, and overall survival (OS) was evaluated using Kaplan-Meier/log-rank tests and multivariable Cox proportional hazards models with covariate adjustment. Results: Severe fatigue, disturbed sleep, and drowsiness were infrequent at baseline and at RT start, but peaked at RT end (26%, 15% and 18%) and returned to near-baseline prevalence by six months after RT (6%, 4%, 2%). In Cox proportional hazard models, severe longitudinal fatigue (HR 5.05, 95% CI 1.25-17.07, p = 0.013), sleep (HR 3.86, 95% CI 1.23 to 10.16, p = 0.0104), and drowsiness burden (HR 8.24, 95% CI 1.22 to 32.62, p = 0.008) were all independently associated with worse OS. Additionally, severe fatigue (HR = 3.58, 95% CI: 1.09 to 10.11, p = 0.0375), sleep disturbance (HR 5.08, 95% CI 1.60-13.51, p = 0.0081), and drowsiness (HR=7.76, 95% CI 1.45-33.47, p=0.0193) reported at RT start were also independently associated with significantly worse OS. Aside from age, severe average daily symptom scores, and severe symptoms reported at RT start, were independently associated with worse OS. Conclusion: Severe sleep related symptoms were uncommon at baseline or RT start, but a substantial proportion of OPC patients experienced clinically meaningful sleep disturbances by the end of RT. At an average follow up of 84 months, severe longitudinal fatigue, sleep, and drowsiness burden were all independently associated with worse OS in OPC. Severe fatigue, drowsiness and sleep disturbance reported at RT start were also independently associated with worse OS. Assessment of sleep disturbances along with potential physiologic correlates are an important part of comprehensive care.
Open AccessSleep-related symptoms are associated with survival in oropharyngeal cancer radiotherapy survivors: Temporal characterization of patient-reported outcomes in a large-scale prospective longitudinal cohort
Purpose: Sleep-related symptom prevalence is not well-characterized and likely under-recognized in head and neck cancer. We investigated longitudinal symptom severity trajectory, prevalence of moderate/severe symptoms, and association between severe sleep-related patient-reported symptoms and oncologic endpoints in oropharyngeal cancer (OPC) patients receiving radiotherapy (RT). Methods: A longitudinal cohort of 372 patients with OPC treated with curative-intent RT with/without chemotherapy at a single-site tertiary center was queried at RT start, end of RT, and six months post-RT. All completed baseline MD Anderson Symptom Inventory-Head and Neck (MDASI-HN) at start of RT. Sleep-related symptom items included “fatigue”, “disturbed sleep”, and “drowsiness” (mild, moderate, severe). Clinical data were collected, and overall survival (OS) was evaluated using Kaplan-Meier/log-rank tests and multivariable Cox proportional hazards models with covariate adjustment. Results: Severe fatigue, disturbed sleep, and drowsiness were infrequent at baseline and at RT start, but peaked at RT end (26%, 15% and 18%) and returned to near-baseline prevalence by six months after RT (6%, 4%, 2%). In Cox proportional hazard models, severe longitudinal fatigue (HR 5.05, 95% CI 1.25-17.07, p = 0.013), sleep (HR 3.86, 95% CI 1.23 to 10.16, p = 0.0104), and drowsiness burden (HR 8.24, 95% CI 1.22 to 32.62, p = 0.008) were all independently associated with worse OS. Additionally, severe fatigue (HR = 3.58, 95% CI: 1.09 to 10.11, p = 0.0375), sleep disturbance (HR 5.08, 95% CI 1.60-13.51, p = 0.0081), and drowsiness (HR=7.76, 95% CI 1.45-33.47, p=0.0193) reported at RT start were also independently associated with significantly worse OS. Aside from age, severe average daily symptom scores, and severe symptoms reported at RT start, were independently associated with worse OS. Conclusion: Severe sleep related symptoms were uncommon at baseline or RT start, but a substantial proportion of OPC patients experienced clinically meaningful sleep disturbances by the end of RT. At an average follow up of 84 months, severe longitudinal fatigue, sleep, and drowsiness burden were all independently associated with worse OS in OPC. Severe fatigue, drowsiness and sleep disturbance reported at RT start were also independently associated with worse OS. Assessment of sleep disturbances along with potential physiologic correlates are an important part of comprehensive care.
- 1 May 2025
- Published by Wolters Kluwer Health in The Cancer Journal
- Vol. 31 (3)
Radiation Techniques for HPV+ Oropharyngeal Cancer
Standard of care for locoregionally advanced HPV-positive OPSCC is definitive chemoradiation with doses up to 70 Gy and concurrent cisplatin. Radiation techniques have evolved considerably from 3D conformal radiotherapy (3D CRT) to the now widely used intensity-modulated radiotherapy (IMRT) and volumetric modulated arc radiotherapy (VMAT). Many centers are also incorporating stereotactic body radiation therapy (SBRT) and proton therapy to deliver even more conformal treatments that can minimize dose to normal organs at risk, thereby improving the therapeutic ratio. We review here the advancements and current landscape of radiation therapy for HPV+ OPSCC.
- 1 May 2025
- Published by Wolters Kluwer Health in The Cancer Journal
- Vol. 31 (3)
Radiation Techniques for HPV+ Oropharyngeal Cancer
Standard of care for locoregionally advanced HPV-positive OPSCC is definitive chemoradiation with doses up to 70 Gy and concurrent cisplatin. Radiation techniques have evolved considerably from 3D conformal radiotherapy (3D CRT) to the now widely used intensity-modulated radiotherapy (IMRT) and volumetric modulated arc radiotherapy (VMAT). Many centers are also incorporating stereotactic body radiation therapy (SBRT) and proton therapy to deliver even more conformal treatments that can minimize dose to normal organs at risk, thereby improving the therapeutic ratio. We review here the advancements and current landscape of radiation therapy for HPV+ OPSCC.
- Open Access
Designing an Electronic Patient Reported Outcomes Information Infrastructure Supported by the RE-AIM Implementation Framework
Objective: Patient-reported outcomes (PROs) contain valuable information that can be leveraged by providers to perform timely interventions and improve quality of life and survival. However, the implementation of electronic PROs (ePROs) remains a challenge from technical, behavioral, and evaluation perspectives. Our objective was to construct a robust electronic health record (EHR)-integrated ePRO information infrastructure founded on RE-AIM (Reach-Effectiveness-Adoption-Implementation-Maintenance) principles. Materials and Methods: We used Epic Systems as our EHR platform to build the MD Anderson Symptom Index-Head and Neck Module (MDASI-HN) for release to all patients undergoing evaluation and/or treatment in our HN Radiation Oncology clinics. RE-AIM metrics were established and used to design patient-, provider-, and implementing facilitator information tools. Results: From January 2021 to July 2024, our ePRO program has collected 13,156 patient-submitted ePROs on 3,497 unique HN patients, with a 12-month sustained ePRO compliance rate of 82%. We also propose a dynamic clinical implementation-evaluation cycle. This model can be used to continuously (re)define, build, and adapt ePRO information tools for patients, providers, and program facilitators. Discussion: Our ePRO framework has several benefits including integrated clinical data for enhanced decision-making, potential scalability, and use of a common EHR system. Formative (i.e., mid-phase) evaluation and feedback were essential in our program, allowing for timely optimization of ePRO compliance, ePRO usage by clinical staff, and secondary use of high-quality ePRO data. Conclusion: In this article, we provide a valuable roadmap towards developing a comprehensive, EHR-based ePRO information infrastructure simultaneously optimized for clinical utility and implementation evaluation founded on RE-AIM principles.
Open AccessDesigning an Electronic Patient Reported Outcomes Information Infrastructure Supported by the RE-AIM Implementation Framework
Objective: Patient-reported outcomes (PROs) contain valuable information that can be leveraged by providers to perform timely interventions and improve quality of life and survival. However, the implementation of electronic PROs (ePROs) remains a challenge from technical, behavioral, and evaluation perspectives. Our objective was to construct a robust electronic health record (EHR)-integrated ePRO information infrastructure founded on RE-AIM (Reach-Effectiveness-Adoption-Implementation-Maintenance) principles. Materials and Methods: We used Epic Systems as our EHR platform to build the MD Anderson Symptom Index-Head and Neck Module (MDASI-HN) for release to all patients undergoing evaluation and/or treatment in our HN Radiation Oncology clinics. RE-AIM metrics were established and used to design patient-, provider-, and implementing facilitator information tools. Results: From January 2021 to July 2024, our ePRO program has collected 13,156 patient-submitted ePROs on 3,497 unique HN patients, with a 12-month sustained ePRO compliance rate of 82%. We also propose a dynamic clinical implementation-evaluation cycle. This model can be used to continuously (re)define, build, and adapt ePRO information tools for patients, providers, and program facilitators. Discussion: Our ePRO framework has several benefits including integrated clinical data for enhanced decision-making, potential scalability, and use of a common EHR system. Formative (i.e., mid-phase) evaluation and feedback were essential in our program, allowing for timely optimization of ePRO compliance, ePRO usage by clinical staff, and secondary use of high-quality ePRO data. Conclusion: In this article, we provide a valuable roadmap towards developing a comprehensive, EHR-based ePRO information infrastructure simultaneously optimized for clinical utility and implementation evaluation founded on RE-AIM principles.
- Open Access
Mandibular dose-volume predicts time-to-osteoradionecrosis in an actuarial normal-tissue complication probability (NTCP) model: External validation of right-censored clinico-dosimetric and competing risk application across international multi-institutional observational cohorts and online graphical user interface clinical support tool assessment
Background Existing studies on osteoradionecrosis of the jaw (ORNJ) have primarily used cross-sectional data, assessing risk factors at a single time point. Determining the time-to-event profile of ORNJ has important implications to monitor oral health in head and neck cancer (HNC) long-term survivors. Methods Demographic, clinical and dosimetric data were retrospectively obtained for a clinical observational cohort of 1129 patients with HNC treated with radiotherapy (RT) at The University of Texas MD Anderson Cancer Center. ORNJ was diagnosed in 198 patients (18%). A multivariable logistic regression analysis with forward stepwise variable selection identified significant predictors for ORNJ. These predictors were then used to train a Weibull Accelerated Failure Time (AFT) model, which was externally validated using an independent cohort of 265 patients (92 ORNJ cases and 173 controls) treated at Guy’s and St. Thomas’ Hospitals. Findings Our model identified that each unit increase in D25% is significantly associated with a 12% shorter time to ORNJ (Adjusted Time Ratio [ATR] 0·88, pInterpretation This study is the first to demonstrate a direct relationship between radiation dose and the time to ORNJ onset, providing a novel characterization of the impact of delivered dose not only on the probability of a late effect (ORNJ), but the conditional risk during survivorship. Funding This work was supported by various funding sources including NIH, NIDCR, NCI, NAPT, NASA, BCM, Affirmed Pharma, CRUK, KWF Dutch Cancer Society, NWO ZonMw, and the Apache Corporation.
Open AccessMandibular dose-volume predicts time-to-osteoradionecrosis in an actuarial normal-tissue complication probability (NTCP) model: External validation of right-censored clinico-dosimetric and competing risk application across international multi-institutional observational cohorts and online graphical user interface clinical support tool assessment
Background Existing studies on osteoradionecrosis of the jaw (ORNJ) have primarily used cross-sectional data, assessing risk factors at a single time point. Determining the time-to-event profile of ORNJ has important implications to monitor oral health in head and neck cancer (HNC) long-term survivors. Methods Demographic, clinical and dosimetric data were retrospectively obtained for a clinical observational cohort of 1129 patients with HNC treated with radiotherapy (RT) at The University of Texas MD Anderson Cancer Center. ORNJ was diagnosed in 198 patients (18%). A multivariable logistic regression analysis with forward stepwise variable selection identified significant predictors for ORNJ. These predictors were then used to train a Weibull Accelerated Failure Time (AFT) model, which was externally validated using an independent cohort of 265 patients (92 ORNJ cases and 173 controls) treated at Guy’s and St. Thomas’ Hospitals. Findings Our model identified that each unit increase in D25% is significantly associated with a 12% shorter time to ORNJ (Adjusted Time Ratio [ATR] 0·88, pInterpretation This study is the first to demonstrate a direct relationship between radiation dose and the time to ORNJ onset, providing a novel characterization of the impact of delivered dose not only on the probability of a late effect (ORNJ), but the conditional risk during survivorship. Funding This work was supported by various funding sources including NIH, NIDCR, NCI, NAPT, NASA, BCM, Affirmed Pharma, CRUK, KWF Dutch Cancer Society, NWO ZonMw, and the Apache Corporation.
- 15 April 2024
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 119 (1) , 8
Less Is More: A Hypofractionated Approach
- 15 April 2024
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 119 (1) , 8
Less Is More: A Hypofractionated Approach
- Open Access
- 7 November 2023
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 44, 100700
Patterns of failure for recurrent head and neck squamous cell carcinoma treated with salvage surgery and postoperative IMRT reirradiation
- 7 November 2023
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 44, 100700
Open AccessPatterns of failure for recurrent head and neck squamous cell carcinoma treated with salvage surgery and postoperative IMRT reirradiation